Navigation Links
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:12/16/2009

hase II study evaluating microplasmin in patients with AMD.

The primary endpoint of both of the MIVI-TRUST trials is the non-surgical resolution of focal vitreomacular adhesion after one month. This anatomical endpoint is being measured and recorded using Optical Coherence Tomography (OCT) which provides images that can clearly show the separation of the vitreous from the retina. OCT is a very sensitive and specific method for detecting the resolution of focal vitreomacular adhesion. In addition to the primary endpoint, the Phase III trials will evaluate additional measures of efficacy as well as safety, assessed at various time periods over the six month study period.

It is expected that the results from the first microplasmin Phase III study, the TG-MV-006 study will be presented in Q2 2010 and the results from the TG-MV-007 study in Q3 2010.

Dr. Patrik De Haes, CEO of ThromboGenics commented, "We are very pleased to announce that we have completed enrolment of our second pivotal Phase III trial for microplasmin, ahead of schedule. Microplasmin is key to the success of our ophthalmic focused strategy and the speed at which patients have been recruited is encouraging. We very much look forward to announcing the first results from our MIVI-TRUST Phase III program by mid 2010."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagu
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 27, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Proteomics - Technologies, ... This report describes and evaluates the proteomic ... drug discovery, molecular diagnostics and practice of medicine ... of the 21st century. Most commonly used technologies ...
(Date:5/28/2015)... May 28, 2015  It takes one act of ... break the cycle of hunger and poverty. AbelsonTaylor marks ... announcing that its recent donation to Heifer International will ... Project (EADD) in Tanzania . The ... and perhaps changing their lives forever. Nearly ...
(Date:5/28/2015)... 2015  Service Strategies Corp., a leading provider ... Kabi, a global healthcare company that specializes in ... clinical nutrition, has achieved certification under the prestigious ... for the seventh consecutive year. ... a stringent set of performance criteria and represent ...
Breaking Medicine Technology:Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 2Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 3AbelsonTaylor Honors World Hunger Day 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3
(Date:5/28/2015)... (PRWEB) May 29, 2015 Recently, KORT Richmond, ... helping amputees regain their quality of life. The program works ... have had one for years, but are still having difficulty. ... nearly 2 million people living with limb loss in the ... (54%) – including diabetes and peripheral arterial disease – trauma ...
(Date:5/28/2015)... 28, 2015 The partners of Urgent ... to present Dr. Alicia Almendral as their chief provider ... part of the newly opened facility’s plan to offer ... cosmetic treatments. , Dr. Almendral is a board certified ... anti-aging and cosmetic enhancement techniques. Her areas of expertise ...
(Date:5/28/2015)... 2015 On Sunday, June 21, 2015, ... team event to honor the strength, passion and endurance ... solstice, the duration of this sunrise-to-sunset event symbolizes the ... their caregivers. Participants raise funds and awareness to advance ... Association. , Teams are encouraged to create their own ...
(Date:5/28/2015)... NJ (PRWEB) May 28, 2015 ... has announced an exclusive deal to patients looking to ... June 1 through 30, patients will be able to ... $800 procedure, for just $600. For a three-treatment package, ... fourth treatment at no cost. , Dr. Juanita Jenyons, ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... By Randy Dotinga HealthDay Reporter , ... that men who undergo prostate removal often suffer more ... counseled beforehand about possible aftereffects. The findings suggest ... cancer expect post-surgery and what actually happens -- and ...
... The U.S. Department of Health and Human Services (HHS) and ... states and the District of Columbia to speed up creation ... health care reform -- across the country. The agencies ... include tax relief to give families and small businesses "the ...
... Aug. 12 (HealthDay News) -- Although being physically active is ... pain and improve their ability to get around, a new ... more sedentary than previously thought. Researchers from Northwestern University ... women and 40 percent of men with knee osteoarthritis are ...
... American Journal of Industrial Medicine reveals that the ... City Fire Department (FDNY) resulting in more post-9/11 retirements ... Chief Medical Officer, FDNY, researchers assessed a total of ... 10, 2008, comparing the total number of retirements and ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, Aug. 12 ... die from sudden cardiac arrest during practice or a game ... mandatory electrocardiograms to screen players for possibly fatal heart defects. ... don,t always get it right when reading these tests, known ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Aug. 11 ... now been infected with an outbreak strain of Salmonella ... Inc., the latest report from the U.S. Centers for Disease ... 76 cases in 26 states. Still, only one death from ...
Cached Medicine News:Health News:Many Men Underestimate Prostate Surgery Side Effects 2Health News:Many Men Underestimate Prostate Surgery Side Effects 3Health News:Feds Outline Rules for States' Insurance Exchanges 2Health News:Many Arthritis Patients May Not Be Exercising Enough 2Health News:Cardiologists Often Miss Heart Defects in Young Athletes: Study 2Health News:Cardiologists Often Miss Heart Defects in Young Athletes: Study 3Health News:Salmonella Outbreak Linked to Turkey Sickens More People 2Health News:Salmonella Outbreak Linked to Turkey Sickens More People 3Health News:Salmonella Outbreak Linked to Turkey Sickens More People 4
Nicati foreign body spud....
... from MMA/VP material and has a high water ... with the base curve and total diameter as ... in a power range of -30.00DS to +30.00DS,Simplon ... and therapeutic applications including the controlled on-eye delivery ...
Optik K & Rs bandage lens is a high water content, therapeutic lens which is ideal for practitioners who recognize the importance of a quality bandage lens....
Bandage lenses....
Medicine Products: